Medical equipment maker Revvity surpassed fourth-quarter estimates and projected 2026 revenue and profit above Wall Street expectations. The company anticipates adjusted profit per share of $5.35 to $5.45, with annual sales between $2.96 billion and $2.99 billion. CEO Prahlad Singh attributed the success to a strong finish in 2025. Industry peers also reported positive results recently. Revvity’s diagnostics unit, with 7% organic growth, outperformed expectations with revenue of $390.1 million. The life sciences unit, with revenue of $382 million, slightly missed estimates. Quarterly adjusted profit was $1.70 per share, and sales totaled $772.1 million.

Read more at Yahoo Finance: Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter